Literature DB >> 21968080

Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study.

W C Chang1, Christy L M Hui, Jennifer Y M Tang, Gloria H Y Wong, May M L Lam, Sherry K W Chan, Eric Y H Chen.   

Abstract

BACKGROUND: Negative symptoms are a core feature of schizophrenia. The evolution and trajectory of primary negative symptoms were under-studied. We aimed at evaluating the prevalence and stability of primary negative symptoms, and factors associated with persistent primary negative symptoms in a first-episode sample.
METHOD: Ninety-three Hong Kong Chinese aged 18 to 55 years presenting with first-episode schizophrenia-spectrum disorder were studied. Data on premorbid adjustment, socio-demographics, and baseline clinical and cognitive profiles were obtained. Psychopathological and vocational reassessments were conducted at 12, 24 and 36 months. Primary negative symptoms were defined as the presence of clinically significant negative symptoms excluding depression and extra-pyramidal signs.
RESULTS: At baseline, 25.8% of subjects exhibited primary negative symptoms. A quarter of patients had their initial primary negative symptoms status retained 12 months after treatment initiation. In both Year 2 and Year 3 of study period, around 70% of subjects had their primary negative symptoms status maintained for 12 months. At the end of three-year follow-up, 23.7% were categorized as having persistent primary negative symptoms. Male sex, unemployment at intake, prolonged duration of untreated psychosis, poorer premorbid academic and social functioning, poorer insight and worse vocational outcome were found to be associated with persistent primary negative symptoms.
CONCLUSION: Clinical status of primary negative symptoms in first-episode schizophrenia-spectrum disorder was unstable in the initial year of treatment. Baseline symptom assessment may not reliably predict development of persistent primary negative symptoms. Studying negative symptoms should take into account the longitudinal perspective, especially in the early course of psychotic disorders.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21968080     DOI: 10.1016/j.schres.2011.09.006

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  27 in total

1.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

2.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

3.  What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Ilja Spellmann; Richard Musil; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

4.  Early-Stage Negative Symptom Trajectories and Relationships With 13-Year Outcomes in First-Episode Nonaffective Psychosis.

Authors:  Wing Chung Chang; Ryan Wui Hang Ho; Jennifer Yee Man Tang; Corine Sau Man Wong; Christy Lai Ming Hui; Sherry K W Chan; Edwin M H Lee; Yi Nam Suen; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

5.  Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics study.

Authors:  Joseph J Shenker; Sarojini M Sengupta; Ridha Joober; Ashok Malla; M Mallar Chakravarty; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2017-05       Impact factor: 6.186

6.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

Authors:  Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-12-08       Impact factor: 4.939

7.  The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.

Authors:  Kenneth L Subotnik; Joseph Ventura; Denise Gretchen-Doorly; Gerhard S Hellemann; Elisha R Agee; Laurie R Casaus; John S Luo; Kathleen F Villa; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-08-06       Impact factor: 4.939

8.  Normal sexual dimorphism in theory of mind circuitry is reversed in Schizophrenia.

Authors:  Julie Walsh-Messinger; Christine Stepanek; Julia Wiedemann; Deborah Goetz; Raymond R Goetz; Dolores Malaspina
Journal:  Soc Neurosci       Date:  2018-10-29       Impact factor: 2.083

9.  Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population.

Authors:  David C Cicero; Elizabeth A Martin; Theresa M Becker; Anna R Docherty; John G Kerns
Journal:  Psychol Assess       Date:  2014-04-07

10.  Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.

Authors:  D J Devoe; L Lu; T D Cannon; K S Cadenhead; B A Cornblatt; T H McGlashan; D O Perkins; L J Seidman; M T Tsuang; S W Woods; E F Walker; D H Mathalon; C E Bearden; J Addington
Journal:  Schizophr Res       Date:  2020-04-30       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.